Arvinas, Inc.

NasdaqGS:ARVN Stock Report

Market Cap: US$1.3b

Arvinas Future Growth

Future criteria checks 2/6

Arvinas is forecast to grow earnings and revenue by 23.5% and 27.2% per annum respectively. EPS is expected to grow by 26.5% per annum. Return on equity is forecast to be -91.3% in 3 years.

Key information

23.5%

Earnings growth rate

26.5%

EPS growth rate

Pharmaceuticals earnings growth20.1%
Revenue growth rate27.2%
Future return on equity-91.3%
Analyst coverage

Good

Last updated16 Jan 2025

Recent future growth updates

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aug 02
Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Recent updates

Arvinas' Vepdegestrant: Why The Data May Not Hold Up

Dec 25

Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans

Dec 24
Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans

Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN)

Nov 28
Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN)

Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause

Oct 16

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aug 02
Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive

Jul 12

Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Jun 27
Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Arvinas: Behind The Huge Rally

Mar 03

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Feb 25
What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Aug 13
News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

May 05
There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Feb 24
Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Arvinas initiated Overweight at Barclays on attractive therapeutic platform

Sep 09

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Aug 19

Earnings and Revenue Growth Forecasts

NasdaqGS:ARVN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027368-283-270-28412
12/31/2026257-364-308-34317
12/31/2025214-341-290-35220
12/31/2024265-225-175-22820
9/30/2024161-309-260-258N/A
6/30/202493-323-217-215N/A
3/31/202471-355-356-354N/A
12/31/202379-367-351-348N/A
9/30/2023159-295-340-336N/A
6/30/2023158-298-323-318N/A
3/31/2023137-301-313-308N/A
12/31/2022131-282-280-273N/A
9/30/2022127-253-246-238N/A
6/30/2022103-233503510N/A
3/31/202275-213536541N/A
12/31/202154-191555559N/A
9/30/202123-180562566N/A
6/30/202121-164-142-138N/A
3/31/202121-139-118-112N/A
12/31/202026-119-96-90N/A
9/30/202024-99-83-77N/A
6/30/202047-86-59-53N/A
3/31/202045-78-52-45N/A
12/31/201943-70-47-41N/A
9/30/201942-65-42-37N/A
6/30/201915-173-54-50N/A
3/31/201914-179-51-48N/A
12/31/201814-240-19-16N/A
9/30/201813-2332224N/A
6/30/201812-114N/A28N/A
3/31/201810-98N/A31N/A
12/31/20178-29N/A5N/A
12/31/20167-12N/A-19N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARVN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ARVN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ARVN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ARVN's revenue (27.2% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: ARVN's revenue (27.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ARVN is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 05:58
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Arvinas, Inc. is covered by 30 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
null nullBMO Capital Markets Equity Research
Etzer DaroutBMO Capital Markets Equity Research